VOLTAREN RAPID 25 diclofenac potassium 25 mg tablet blister pack

Ülke: Avustralya

Dil: İngilizce

Kaynak: Department of Health (Therapeutic Goods Administration)

Aktif bileşen:

diclofenac potassium, Quantity: 25 mg

Mevcut itibaren:

Haleon Australia Pty Ltd

Farmasötik formu:

Tablet, sugar coated

Kompozisyon:

Excipient Ingredients: macrogol 8000; iron oxide red; sucrose; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; purified talc; maize starch; povidone; calcium phosphate; microcrystalline cellulose; titanium dioxide

Uygulama yolu:

Oral

Paketteki üniteler:

4,5,6,10,20 and 30 tablets

Reçete türü:

(S3) Pharmacist Only Medicine

Terapötik endikasyonlar:

As short-term treatment (up to one week) for the relief of acute pain states in which there is an inflammatory component. Symptomatic treatment of primary dysmenorrhoea. INDICATIONS AS AT 16 NOVEMBER 1998: As short-term treatment (up to one week) for the relief of acute pain states in which there is an inflammatory component. Treatment of acute migraine attacks (with or without aura). Symptomatic treatment of primary dysmenorrhoea.

Ürün özeti:

Visual Identification: Pale red, round, biconvex, sugar coated tablets.; Container Type: Blister Pack; Container Life Time: 30 Months; Container Temperature: Store below 30 degrees Celsius

Yetkilendirme durumu:

Registered

Yetkilendirme tarihi:

1993-05-27

Ürün özellikleri

1
AUSTRALIAN PRODUCT INFORMATION
VOLTAREN RAPID 25 (DICLOFENAC POTASSIUM) TABLET
1
NAME OF THE MEDICINE
Diclofenac potassium
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active ingredient: diclofenac potassium 25 mg/tablet.
Each Voltaren Rapid 25 tablet contains 2.9 mg of potassium. Also
contains sugars.
For the full list of excipients, see Section 6.1 List of excipients.
3
PHARMACEUTICAL FORM
Light red, round, biconvex sugar-coated tablets.
4
CLINICAL PARTICULARS
4.1
T
HERAPEUTIC INDICATIONS
•
As short-term treatment for the relief of acute pain states in which
there is an inflammatory
component.
•
Treatment of acute migraine attacks (with or without aura).
•
Symptomatic treatment of primary dysmenorrhoea.
4.2
D
OSE AND METHOD OF ADMINISTRATION
After assessing the risk/benefit ratio in each individual patient, the
lowest effective dose for the
shortest duration should be used. Adverse effects may be minimised by
using the lowest effective
dose for the shortest duration necessary to control symptoms (see
Section 4.4 ‘Special warnings and
precautions for use’).
The tablets should be swallowed whole with water and must not be
divided or chewed. It is
preferable to take the tablets before meals (see section 5.2
Pharmacokinetic Properties –
Absorption).
ADULTS AND CHILDREN AGED 14 YEARS AND OVER:
Voltaren Rapid 25 should not be used for more than a few days at a
time unless on medical advice,
in which case the patient should be reviewed regularly with regards to
efficacy, risk factors and
ongoing need for treatment.
2
As a rule, the initial daily dosage for adults is 100 to 150 mg. In
milder cases, as well as for children
over 14 years of age, 75 to 100 mg daily is usually sufficient. The
daily dosage should generally be
taken in 2 or 3 fractional doses.
In migraine, an initial dose of 50 mg should be taken at the first
signs of an impending attack. If the
pain is not relieved within 2 hours of this initial dose, a further
dose of 50 mg may be taken. If
needed, further doses of 50 mg may be taken at interva